Omeran (Omeprazole)

Omeprazole, the active ingredient in Omeran, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat gastro‑reflux and other acid‑related disorders in adults and children. GNH USA supplies Omeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeran is a proton pump inhibitor that acts on the gastric acid secretion pathway, providing relief in several acid‑related conditions.

- Gastro‑esophageal reflux disease (GERD): helps heal erosive esophagitis and reduces heartburn episodes. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the condition. - Helicobacter pylori eradication regimens (as part of combination therapy): supports ulcer healing when used with antibiotics. - NSA‑related gastric protection: reduces risk of ulcer formation in patients requiring long‑term NSAID therapy.

Adverse reactions to omeprazole are generally mild, but clinicians monitor both common and rare events.

Common Side Effects: - Headache: mild, transient headache reported by some patients. - Diarrhea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements in some individuals.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Acute interstitial nephritis: sudden kidney inflammation. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: life‑threatening skin reactions. - Hypomagnesemia: low magnesium levels with prolonged use. - Fracture risk: increased incidence of hip, wrist or spine fractures with long‑term therapy. - Vitamin B12 deficiency: reduced absorption leading to anemia over extended periods.

When prescribing Omeran, clinicians consider several safety aspects.

- Indication verification: ensure the patient has a confirmed acid‑related disorder. - Duration monitoring: limit long‑term use to the shortest effective period. - Renal impairment: adjust use in patients with severe kidney disease. - Hepatic impairment: use cautiously in moderate to severe liver dysfunction. - Pregnancy and lactation: evaluate risk‑benefit before use in pregnant or breastfeeding women. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir and other protease inhibitors: decreased antiviral efficacy. - Methotrexate (high dose): increased systemic exposure, risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, requiring more frequent monitoring. - Digoxin: possible increase in serum levels. - Phenytoin: reduced serum concentration, may require dose adjustment.